KALA BIO (KALA)

• Market cap: $41.1M
• 1 day: -2.88%
• 5 days: -3.71%
• 1 month: -13.02%
• 3 months: 9.22%
• 6 months: 14.21%
• Year to date: -12.45%
• 1 year: -11.76%
• 5 years: -97.91%
• 10 years: -99.27%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Employees: 43

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 2

99% more capital invested

Capital invested by funds: $12.1M [Q3] → $24M (+$11.9M) [Q4]

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

29.13% more ownership

Funds ownership: 45.92% [Q3] → 75.06% (+29.13%) [Q4]

22% more funds holding

Funds holding: 27 [Q3] → 33 (+6) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 122% upside
• Avg. target: $15 122% upside
• High target: $15 122% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Yi Chen 36% 1-year accuracy 58 / 160 met price target

122% upside $15

Buy Reiterated

13 Feb 2025